Small Cell Carcinoma Of Lung — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for small cell carcinoma of lung. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
4
Active US patents
73/100
Avg vulnerability
—
Annual revenue covered

Originators in Small Cell Carcinoma Of Lung

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Jazz Pharmaceuticals 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating small cell carcinoma of lung. Each bar = one year. Y-axis scaled to peak year (3 patents).

1
29
3
40

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zepzelca
LURBINECTEDIN
 Jazz Pharmaceuticals 4 73 — 2029-12-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12324806 Zepzelca method of use 75 2040-05-29
12433890 Zepzelca method of use 75 2040-05-29
12440490 Zepzelca method of use 75 2040-05-29
7763615 Zepzelca method of use 68 2029-12-13

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7763615 Zepzelca method of use 68 2029-12-13
12324806 Zepzelca method of use 75 2040-05-29
12433890 Zepzelca method of use 75 2040-05-29
12440490 Zepzelca method of use 75 2040-05-29

Related